Eikonoklastes Therapeutics: Funding, Investors & Team (Oct 2026)
Eikonoklastes Therapeutics is developing a range of innovative therapies that can quickly and cost-effectively progress from preclinical to clinical stages for approval. We have obtained our initial two treatments for poorly managed diseases and focus on compounds that can address multiple severe medical needs, receive priority regulatory attention, and require minimal clinical trials for approval. Our first gene therapy, ET-101, aims to treat various neurodegenerative diseases by enhancing the expression of Caveolin-1, which regulates synaptic receptors crucial for nerve signaling. Additionally, our tissue factor therapy, ET-201, targets a cell receptor prevalent in tumor cells to inhibit tumor growth and spread. Initial targeted diseases include ALS and triple negative breast cancer, with plans to explore other conditions like Alzheimer's and ovarian cancer in the future.
Eikonoklastes Therapeutics has raised $16.8M across 2 funding rounds on record, the most recent an undisclosed round of $13.6M announced in Jul 2025.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Eikonoklastes Therapeutics Company Profile and Key Stats
Latest funding round on record: Jul 2025.
Eikonoklastes Therapeutics Funding Rounds
Eikonoklastes Therapeutics raised $3.2M in an undisclosed round announced in May 2021.
4.2 years later, an undisclosed round of $13.6M was announced in Jul 2025.
Eikonoklastes Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Eikonoklastes Therapeutics Funding Compared to Other Biotechnology Startups
Eikonoklastes Therapeutics' latest round of $13.6M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Eikonoklastes Therapeutics in Biotechnology and Cincinnati
Companies Similar to Eikonoklastes Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Eikonoklastes Therapeutics Funding FAQs
What does Eikonoklastes Therapeutics do?
Eikonoklastes Therapeutics is developing a range of innovative therapies that can quickly and cost-effectively progress from preclinical to clinical stages for approval. We have obtained our initial two treatments for poorly managed diseases and focus on compounds that can address multiple severe medical needs, receive priority regulatory attention, and require minimal clinical trials for approval. Our first gene therapy, ET-101, aims to treat various neurodegenerative diseases by enhancing the expression of Caveolin-1, which regulates synaptic receptors crucial for nerve signaling. Additionally, our tissue factor therapy, ET-201, targets a cell receptor prevalent in tumor cells to inhibit tumor growth and spread. Initial targeted diseases include ALS and triple negative breast cancer, with plans to explore other conditions like Alzheimer's and ovarian cancer in the future.
How much funding has Eikonoklastes Therapeutics raised?
Eikonoklastes Therapeutics has raised $16.8M across 2 rounds on record. The most recent is an undisclosed round of $13.6M announced in Jul 2025.
When did Eikonoklastes Therapeutics last raise funding?
Eikonoklastes Therapeutics' most recent funding round on record is an undisclosed round of $13.6M, announced in Jul 2025.
Who founded Eikonoklastes Therapeutics?
FundedIQ lists Samuel Lee (Founder) at Eikonoklastes Therapeutics.
Who is the CEO of Eikonoklastes Therapeutics?
Bruce Halpryn is listed as CEO at Eikonoklastes Therapeutics.
Where is Eikonoklastes Therapeutics headquartered?
Eikonoklastes Therapeutics is based in Cincinnati, Ohio, United States.
How many employees does Eikonoklastes Therapeutics have?
Eikonoklastes Therapeutics is in the 1-10 employee band.
How does Eikonoklastes Therapeutics' funding compare to other Biotechnology startups?
Eikonoklastes Therapeutics' latest round of $13.6M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Eikonoklastes Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Eikonoklastes Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.